Fat-dissolving injections

Injectables marketed to dissolve localized fat: one FDA-approved product exists (deoxycholic acid / Kybella, for under-chin fat, physician-administered), surrounded by unapproved "lipolysis solutions" — Lemon Bottle (a riboflavin/lecithin/bromelain mix) being the best-known.

These are injections intended to destroy fat cells locally. The one with an approved basis is deoxycholic acid, a bile acid the body already makes, which disrupts fat cell membranes so the cells break down and are cleared — approved for submental fullness, the fat under the chin. It is a detergent-like cytolytic agent with relative selectivity for fat in the body, because protein-rich tissue and albumin blunt its action elsewhere. That selectivity is partial, not absolute: misplaced exposure still injures skin, muscle, blood vessels and nerves. Everything else in this category — phosphatidylcholine blends, unbranded "lipolytic" cocktails — lacks that approval and often lacks any characterised composition.

Kybella has RCTs for one small anatomical area. Lemon Bottle and its cousins have no published controlled evidence at all — the viral before/afters are marketing, and the ingredient list does not contain an established lipolytic mechanism at cosmetic doses.

• STRONG for the approved deoxycholic acid product in its approved indication, submental fat, on randomised trials.
• LIMITED for body contouring elsewhere — small human studies exist outside the submental area, including a 37-person within-person randomised study and a 13-person abdominal study. The regulatory fact is stronger than the evidence: FDA has not established the approved product's safety or effectiveness anywhere except under the chin.
• The trial incidences are higher than "rare" suggests and deserve stating: marginal mandibular nerve paresis occurred in 4% of recipients against under 1% on placebo, and DYSPHAGIA — difficulty swallowing — in 2%. Injection-site reactions occurred in 96%, including swelling in 87%, bruising in 72%, pain in 70% and numbness in 66%, some persisting beyond 30 days.
• Skin ulceration and tissue necrosis have occurred, particularly with injection into the wrong tissue plane, and FDA has warned specifically about unapproved injectable products marketed for fat dissolving.
• The unapproved products are the bigger problem: composition is often undisclosed, and adverse events including infection, disfigurement and hospitalisation have been reported with products bought online or administered by untrained injectors.

Deoxycholic acid acts locally at the injection site by disrupting cell membranes, with partial selectivity for fat conferred by tissue protein binding rather than by targeting. Do not self-inject. The only FDA-approved fat-dissolving injectable is for adult submental fat and is administered by a licensed healthcare professional; FDA has reported serious injuries from unapproved products.

Kybella's own trials document swelling, nodules, numbness, and rare marginal-mandibular nerve injury — with a physician injecting. Unapproved injections add infection, scarring, tissue injury (necrosis case reports exist in the aesthetics literature), and total composition uncertainty.

• CONTRAINDICATED per the label: infection at the injection site
• Anyone with current or prior difficulty swallowing, which treatment may worsen — this is an avoidance condition and it is frequently missed
• PRECAUTIONS requiring assessment rather than automatic exclusion: bleeding disorders, anticoagulant or antiplatelet use, and prior surgery or altered anatomy in the treatment area
• Anyone considering an unapproved or unbranded lipolytic product, or any product bought online — FDA has reported serious injuries from these
• Do not self-inject under any circumstances

• Anticoagulants and antiplatelet drugs, which increase bruising and bleeding at injection sites.
• Any bleeding disorder.
• Prior surgery or existing anatomical distortion in the treatment area, which changes where the structures a needle must avoid actually are.

• Who is injecting and what they are injecting — this is the variable that determines outcome, more than anything about the compound.
• Any facial weakness, asymmetric smile or difficulty swallowing after treatment, which suggests nerve involvement and needs immediate assessment.
• Skin colour change, blanching, severe pain or breakdown at the site — these can precede ulceration or necrosis and are urgent.
• Signs of infection, particularly with unapproved product or non-clinical settings.

This is a procedure rather than an ongoing treatment, so there is nothing to stop. Injection-site reactions occurred in 96% of trial recipients and some persisted beyond 30 days. Nerve paresis usually recovers but can take months. Ulceration and necrosis leave permanent scarring. Both what is injected and who injects it determine outcome, and FDA has reported serious injuries from unapproved products.

US: Kybella is prescription/physician-use. The FDA has warned that unapproved fat-dissolving injections are unapproved drugs and can be harmful — a product marketed to alter body structure is a drug regardless of "cosmetic" labeling.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Efficacy, safety, and potential industry bias in using deoxycholic acid for submental fat reduction ‒ A systematic review and meta-analysis of randomized clinical trials
  Clinics (Sao Paulo), 2023
• Is deoxycholic acid able to reduce submental fat and increase patient satisfaction when compared to placebo groups? A systematic review
  J Plast Reconstr Aesthet Surg, 2022
• Efficacy and safety of injectable deoxycholic acid for submental fat reduction: a systematic review and meta-analysis of randomized controlled trials
  Expert Rev Clin Pharmacol, 2021

Not auto-graded. This entry covers several different drugs, or a use the published research was never about, so no single letter honestly describes it. The reading below is real literature — read it against what this page says, not as a score.

• Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA deliveryTheranostics · 2024
• Deoxycholic acid ameliorates obesity and insulin resistance by enhancing lipolysis and thermogenesisLipids Health Dis · 2025
• Neck Rejuvenation2026
• [Injection lipolysis]Hautarzt · 2010
• Evaluating the Efficacy and Safety of Deoxycholic Acid Injection in Reduction of Flank FatJ Cosmet Dermatol · 2025
• ATX-101 (deoxycholic acid injection) for reduction of submental fatExpert Rev Clin Pharmacol · 2016
• Male Body ContouringJ Drugs Dermatol · 2015
• Uncommon Adverse Effects of Deoxycholic Acid Injection for Submental Fullness: Beyond the Clinical TrialsJ Cutan Med Surg · 2020
• Deoxycholic acid in the submental fat reduction: A review of properties, adverse effects, and complicationsJ Cosmet Dermatol · 2020
• Overview of ATX-101 (Deoxycholic Acid Injection): A Nonsurgical Approach for Reduction of Submental FatDermatol Surg · 2016
• Alternative Cosmetic and Medical Applications of Injectable Deoxycholic Acid: A Systematic ReviewDermatol Surg · 2021
• Safety and Efficacy of Deoxycholic Acid Injection for Hypogastric Fat Reduction: A Pilot StudyDermatol Surg · 2021